Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice

Objective: to assess bone mineral density (BMD) changes in rheumatoid arthritis (RA) patients with osteoporosis (OP) and in women with postmenopausal OP during therapy with denosumab (DSB) for 1 yearSubjects and methods. 121 women were included: the main group – 69 patients with RA (mean age – 60±7...

Full description

Bibliographic Details
Main Authors: O. V. Dobrovolskaya, P. S. Kovalenko, N. V. Toroptsova, I. S. Dydykina, O. A. Nikitinskaya, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2019-05-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2699
id doaj-d2c6455c4fc1443b8cdd94f456aff5dd
record_format Article
spelling doaj-d2c6455c4fc1443b8cdd94f456aff5dd2021-08-02T09:05:52ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922019-05-0157216016510.14412/1995-4484-2019-160-1652470Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practiceO. V. Dobrovolskaya0P. S. Kovalenko1N. V. Toroptsova2I. S. Dydykina3O. A. Nikitinskaya4E. L. Nasonov5V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaObjective: to assess bone mineral density (BMD) changes in rheumatoid arthritis (RA) patients with osteoporosis (OP) and in women with postmenopausal OP during therapy with denosumab (DSB) for 1 yearSubjects and methods. 121 women were included: the main group – 69 patients with RA (mean age – 60±7 years), 34 (49.3%) from them received glucocorticoids (GC). Comparison group comprised 52 women with primary OP (mean age – 62±10 years). Measurement of BMD using dual-energy X-ray absorptiometry (DXA) was performed in the lumbar spine (LI–IV), femoral neck (FN), proximal femur as a whole (PF) and distal forearm (DF). DSB was administered subcutaneously at a dose of 60 mg 1 time in 6 months.Results and discussion. In patients with RA, the average increase of BMD for 12 months of treatment was: in LI–IV – 4.6%, in FN-2.8%, in PF-3.0% and in DF-0.7%, and in the comparison group – 5.2; 2.1; 2.9 and 0.9%, respectively. There were no significant differences of BMD changes between the groups. Efficacy of DSB therapy in RA patients with OP did not depend on RA activity, duration of GC therapy and cumulative dose of GC. Adverse events that did not lead to the withdrawal of the drug were noted in 3% of the study participants. There were no fractures during the observation.Conclusion. The efficacy treatment with DSB for 1 year in RA patients with OP and in women with postmenopausal OP is comparable. The use of GC did not have a negative impact on DSB effect.https://rsp.mediar-press.net/rsp/article/view/2699rheumatoid arthritispostmenopausal osteoporosissecondary osteoporosisglucocorticoid osteoporosisbone mineral densitydenosumabglucocorticoids
collection DOAJ
language Russian
format Article
sources DOAJ
author O. V. Dobrovolskaya
P. S. Kovalenko
N. V. Toroptsova
I. S. Dydykina
O. A. Nikitinskaya
E. L. Nasonov
spellingShingle O. V. Dobrovolskaya
P. S. Kovalenko
N. V. Toroptsova
I. S. Dydykina
O. A. Nikitinskaya
E. L. Nasonov
Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
Научно-практическая ревматология
rheumatoid arthritis
postmenopausal osteoporosis
secondary osteoporosis
glucocorticoid osteoporosis
bone mineral density
denosumab
glucocorticoids
author_facet O. V. Dobrovolskaya
P. S. Kovalenko
N. V. Toroptsova
I. S. Dydykina
O. A. Nikitinskaya
E. L. Nasonov
author_sort O. V. Dobrovolskaya
title Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
title_short Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
title_full Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
title_fullStr Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
title_full_unstemmed Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
title_sort comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2019-05-01
description Objective: to assess bone mineral density (BMD) changes in rheumatoid arthritis (RA) patients with osteoporosis (OP) and in women with postmenopausal OP during therapy with denosumab (DSB) for 1 yearSubjects and methods. 121 women were included: the main group – 69 patients with RA (mean age – 60±7 years), 34 (49.3%) from them received glucocorticoids (GC). Comparison group comprised 52 women with primary OP (mean age – 62±10 years). Measurement of BMD using dual-energy X-ray absorptiometry (DXA) was performed in the lumbar spine (LI–IV), femoral neck (FN), proximal femur as a whole (PF) and distal forearm (DF). DSB was administered subcutaneously at a dose of 60 mg 1 time in 6 months.Results and discussion. In patients with RA, the average increase of BMD for 12 months of treatment was: in LI–IV – 4.6%, in FN-2.8%, in PF-3.0% and in DF-0.7%, and in the comparison group – 5.2; 2.1; 2.9 and 0.9%, respectively. There were no significant differences of BMD changes between the groups. Efficacy of DSB therapy in RA patients with OP did not depend on RA activity, duration of GC therapy and cumulative dose of GC. Adverse events that did not lead to the withdrawal of the drug were noted in 3% of the study participants. There were no fractures during the observation.Conclusion. The efficacy treatment with DSB for 1 year in RA patients with OP and in women with postmenopausal OP is comparable. The use of GC did not have a negative impact on DSB effect.
topic rheumatoid arthritis
postmenopausal osteoporosis
secondary osteoporosis
glucocorticoid osteoporosis
bone mineral density
denosumab
glucocorticoids
url https://rsp.mediar-press.net/rsp/article/view/2699
work_keys_str_mv AT ovdobrovolskaya comparativeevaluationofdenosumabefficacyofinpatientswithrheumatoidarthritisandpostmenopausalosteoporosisresultsof1yearstudyinclinicalpractice
AT pskovalenko comparativeevaluationofdenosumabefficacyofinpatientswithrheumatoidarthritisandpostmenopausalosteoporosisresultsof1yearstudyinclinicalpractice
AT nvtoroptsova comparativeevaluationofdenosumabefficacyofinpatientswithrheumatoidarthritisandpostmenopausalosteoporosisresultsof1yearstudyinclinicalpractice
AT isdydykina comparativeevaluationofdenosumabefficacyofinpatientswithrheumatoidarthritisandpostmenopausalosteoporosisresultsof1yearstudyinclinicalpractice
AT oanikitinskaya comparativeevaluationofdenosumabefficacyofinpatientswithrheumatoidarthritisandpostmenopausalosteoporosisresultsof1yearstudyinclinicalpractice
AT elnasonov comparativeevaluationofdenosumabefficacyofinpatientswithrheumatoidarthritisandpostmenopausalosteoporosisresultsof1yearstudyinclinicalpractice
_version_ 1721235689894313984